Cell Therapeutics Signs Deal With Norvatis

Cell Therapeutics (CTIC) has signed a worldwide licensing deal with Norvartis worth US$285M. This agreement will see Norvatis assisting in the development and commercialisation of Cell Therapeutics’ flagship drug, XYOTAX. The amount includes US$15M equity investment in the drug development company as well.

Cell Therapeutics traded up 13 cents or 6.67% on Monday to $2.08.

Technorati Tags: , , , , , , , ,


Leave a Reply

Your email address will not be published. Required fields are marked *

Spam protection by WP Captcha-Free